UNSPSC 51172479: Potassium bicarbonate/sodium bicarbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA110. This VA Drug Class (GA110) classifies this compound as belonging to the group SODIUM BICARBONATE CONTAINING ANTACIDS.

UNSPSC 51172479 Potassium bicarbonate/sodium bicarbonate is a Commodity code that shows minimal relevance to recent state and local procurement activity. The three most recent opportunities tagged to this code involve offender drug testing services (Collin County), a pharmacy benefit program RFI (Texas HHS), and generic pharmaceutical and OTC product distribution (Minnesota MMCAP cooperative purchasing), none of which directly specify potassium bicarbonate or sodium bicarbonate as the procurement subject. The code's nominal scope — chemical compounds — does not align with the actual work being solicited under it in the current market.

Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, while the Minnesota Department of Administration's MMCAP office solicited generic multi-source pharmaceuticals and OTC products under RFP S1070000015802, due March 26, 2026, for distribution across participating state and local facilities in Minnesota and Oregon. These solicitations reflect state and local interest in pharmacy services and drug testing infrastructure rather than chemical supply. The code appears to carry a tagging mismatch in the procurement database; unless potassium or sodium bicarbonate is a minor reagent or test-related input in the drug-testing or pharmaceutical offerings, this code does not represent a meaningful market opportunity under its nominal definition.